Vasorelaxant and antiaggregatory actions of the nitroxyl donor isopropylamine NONOate are maintained in hypercholesterolemia

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 4, 2011, Pages

  Bullen, Michelle L ^a   Miller, Alyson A ^a   Dharmarajah, Janahan ^a   Drummond, Grant R ^a   Sobey, Christopher G ^a   Kemp Harper, Barbara K ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Nitric oxide; Platelet aggregation; Vasorelaxation

Indexed keywords

APOLIPOPROTEIN E; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; COLLAGEN; CYCLIC GMP; CYSTEINE; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; ISOPROPYLAMINE NONOATE; PAPAVERINE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD VESSEL FUNCTION; CARDIOVASCULAR FUNCTION; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; HEART PROTECTION; HYPERCHOLESTEROLEMIA; LIPID DIET; MALE; MOUSE; NONHUMAN; PREMEDICATION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT RESPONSE; VASODILATATION;

ANIMALS; APOLIPOPROTEINS E; CAROTID ARTERY, COMMON; CHOLESTEROL; COLLAGEN; DIETARY FATS; FREE RADICAL SCAVENGERS; HYDRAZINES; HYPERCHOLESTEROLEMIA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROGLYCERIN; OXIDATIVE STRESS; PLATELET AGGREGATION INHIBITORS; SUPEROXIDES; VASODILATOR AGENTS;

EID: 80053265640     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00489.2011     Document Type: Article

References (29)

1. Bermejo E, Saenz DA, Alberto F, Rosenstein RE, Bari SE, Lazzari MA. Effect of nitroxyl on human platelets function. Thromb Haemost 94: 578-584, 2005.
2. Bullen ML, Miller AA, Andrews KL, Irvine J, Ritchie RH, Sobey C, Kemp-Harper B. Nitroxyl (HNO) as a vasoprotective signaling molecule. Antioxid Redox Signal 14: 1675-1686, 2011.
3. Chirkov YY, Horowitz JD. Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier? Pharmacol Ther 116: 287-305, 2007.
4. Daiber A, Wenzel P, Oelze M, Munzel T. New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance. Clin Res Cardiol 97: 12-20, 2008.
5. Dangel O, Mergia E, Karlisch K, Groneberg D, Koesling D, Friebe A. Nitric oxide-sensitive guanylyl cyclase is the only nitric oxide receptor mediating platelet inhibition. J Thromb Haemost 8: 1343-1352, 2010.
6. Dharmarajah J, Arthur JF, Sobey CG, Drummond GR. The antiplatelet effects of apocynin in mice are not mediated by inhibition of NADPH oxidase activity. Naunyn Schmiedebergs Arch Pharmacol 382: 377-384, 2010.
7. Favaloro JL, Kemp-Harper B. Redox variants of NO (NO• and HNO) elict vasorelaxation of resistance arteries via distinct mechanisms. Am J Physiol Heart Circ Physiol 296: H1274-H1280, 2009.
8. Favaloro JL, Kemp-Harper BK. The nitroxyl anion (HNO) is a potent dilator of rat coronary vasculature. Cardiovasc Res 73: 587-596, 2007.
9. Fukuto JM, Chiang K, Hszieh R, Wong P, Chaudhuri G. The pharmacological activity of nitroxyl: a potent vasodilator with activity similar to nitric oxide and/or endothelium-derived relaxing factor. J Pharmacol Exp Ther 263: 546-551, 1992.
10. Irvine J, Kemp-Harper BK, Widdop RE. Chronic administration of the HNO donor, Angeli's salt does not lead to tolerance, cross-tolerance or endothelial dysfunction: comparison with GTN and DEA/NO. Antioxid Redox Signal 14: 1615-1624, 2011.
11. - activates soluble guanylate cyclase and Kv channels to vasodilate resistance arteries. Hypertension 41: 1301-1307, 2003.
12. Irvine JC, Favaloro JL, Widdop RE, Kemp-Harper BK. Nitroxyl anion donor, Angeli's salt, does not develop tolerance in rat isolated aortae. Hypertension 49: 885-892, 2007.
13. Irvine JC, Ritchie RH, Favaloro JL, Andrews KL, Widdop RE, Kemp-Harper BK. Nitroxyl (HNO): the Cinderella of the nitric oxide story. Trends Pharmacol Sci 29: 601-608, 2008.
14. -/- mice. Am J Physiol Heart Circ Physiol 298: H24-H32, 2010.
15. Kitayama J, Faraci FM, Lentz SR, Heistad DD. Cerebral vascular dysfunction during hypercholesterolemia. Stroke 38: 2136-2141, 2007.
16. Melichar VO, Behr-Roussel D, Zabel U, Uttenthal LO, Rodrigo J, Rupin A, Verbeuren TJ, Kumar HS, Schmidt HH. Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc Natl Acad Sci USA 101: 16671-16676, 2004.
17. Miller AA, De Silva TM, Judkins CP, Diep H, Drummond GR, Sobey CG. Augmented superoxide production by Nox2-containing NADPH oxidase causes cerebral artery dysfunction during hypercholesterolemia. Stroke 41: 784-789, 2010.
18. Miranda K, Paolocci N, Katori T, Thomas DD, Ford E, Bartberger MD, Espey MG, Kass DA, Feelisch M, Fukuto JM, Wink DA. A biochemical rationale for the discrete behavior of nitroxyl and nitric oxide in the cardiovascular system. Proc Natl Acad Sci USA 100: 9196-9201, 2003.
19. Miranda KM, Katori T, Torres de Holding CL, Thomas L, Ridnour LA, McLendon WJ, Cologna SM, Dutton AS, Champion HC, Mancardi D, Tocchetti CG, Saavedra JE, Keefer LK, Houk KN, Fukuto JM, Kass DA, Paolocci N, Wink DA. Comparison of the NO and HNO donating properties of diazeniumdiolates: primary amine adducts release HNO in Vivo. J Med Chem 48: 8220-8228, 2005.
20. Miranda KM, Yamada K, Espey MG, Thomas DD, DeGraff W, Mitchell JB, Krishna MC, Colton CA, Wink DA. Further evidence for distinct reactive intermediates from nitroxyl and peroxynitrite: effects of buffer composition on the chemistry of Angeli's salt and synthetic peroxynitrite. Arch Biochem Biophys 401: 134-144, 2002.
21. Mondoro TH, Ryan BB, Hrinczenko BW, Schechter AN, Vostal JG, Alayash AI. Biological action of nitric oxide donor compounds on platelets from patients with sickle cell disease. Br J Haematol 112: 1048-1054, 2001.
22. - in failing hearts: Independence from -adrenergic signalling. Proc Natl Acad Sci USA 100: 5537-5542, 2003.
23. Paolocci N, Saavedra WF, Miranda KM, Martignani C, Isoda T, Hare JM, Espey MG, Fukuto JM, Feelisch M, Wink DA, Kass DA. Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling. Proc Natl Acad Sci USA 98: 10463-10468, 2001.
24. Pignatelli P, Sanguigni V, Lenti L, Loffredo L, Carnevale R, Sorge R, Violi F. Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin. J Thromb Haemost 5: 1170-1178, 2007.
25. Sanguigni V, Pignatelli P, Caccese D, Pulcinelli FM, Lenti L, Magnaterra R, Martini F, Lauro R, Violi F. Increased superoxide anion production by platelets in hypercholesterolemic patients. Thromb Haemost 87: 796-801, 2002.
26. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101: 1899-906, 2000.
27. Switzer CH, Flores-Santana W, Mancardi D, Donzelli S, Basudhar D, Ridnour L, Miranda K, Fukuto JM, Paolocci N, Wink DA. The emergance of nitroxyl (HNO) as a pharmacological agent. Biochim Biophys Acta 1787: 835-840, 2009.
28. + cycling. Circ Res 100: 96-104, 2007.
29. Tsihlis ND, Murar J, Kapadia MR, Ahanchi SS, Oustwani CS, Saavedra JE, Keefer LK, Kibbe MR. Isopropylamine NONOate (IPA/NO) moderates neointimal hyperplasia following vascular injury. J Vasc Surg 51: 1248-1259, 2010.